About 100 reports

  • National Heart Lung and Blood Institute, Key Employees
  • Sep 30, 2016: NHLBI Awards Grants to Help Improve Health Outcomes for Teens, Adults with Sickle...
  • Blood Disease
  • Healthcare
  • Therapy
  • United States
  • GlobalData's company

(GBT), a newly formed product-focused company building a pipeline of oral for the treatment of chronic blood-based diseases and genetic disorders, raised $##. ##m in series A financing round.

  • Blood Disease
  • Therapy
  • World
  • Company
  • GlobalData's company

The products are used to detect infectious diseases and to quantify the level of Haemoglobin A##c and other chemistry parameters in serum, plasma and whole blood.

  • Blood Disease
  • Clinical Trial
  • CT Scan
  • In Vitro Diagnostic Reagent
  • GlobalData's company
  • BIOSIMILARS MARKET SIZE FOR BLOOD DISORDERS, BY REGION, 2014-2021 (USD MILLION)
  • 8.4 BLOOD DISORDERS

The Division of Blood Diseases and Resources (DBDR), a part of the National Heart, Lung, and Blood Institute (NHLBI), supports research on blood diseases such as anemia, sickle cell disease (SCD), and thalassemia.

  • Biosimilar
  • Blood Disease
  • World
  • Market Size
  • Sandoz Inc.
  • Hematology Drugs Market Historic Growth

Hematology drugs market offers drugs, blood and blood products that are used for the treatment of diseases such as rare genetic disorders, anemia, and conditions related to sickle cell disease and other related diseases.

  • Blood Disease
  • World
  • Bayer AG
  • Daiichi Sankyo Company
  • Shire plc
  • Market challenges

These therapies have seen reluctance among the individuals due to the issue of developing inhibitors and further risk of blood-borne diseases.

  • Blood Disease
  • Forecast
  • Market Size
  • Biogen Idec Inc.
  • CSL Behring GmbH
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • M-009 - Drug Profile
  • Blood Disease
  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • M-009 - Drug Profile
  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Blood Disease Drugs Sales Volume
  • Blood Disease Drugs Sales Volume
  • Blood Disease
  • China
  • Trade
  • Lijun Pharmaceutical Co., Ltd.
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd
  • Blood Disease Drugs Sales Volume
  • Blood Disease Drugs Industry Structure
  • Blood Disease
  • Pharmaceutical
  • China
  • Demand
  • Eisai Co., Ltd.
  • Blood Disease Drugs Sales Volume
  • Other Blood Disease Drugs
  • Blood Disease
  • China
  • Demand
  • Market Size
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd
  • PIPELINE BY BELLICUM PHARMACEUTICALS, INC., H2 2016
  • PIPELINE BY BELLICUM PHARMACEUTICALS INC, H2 2017

IT IS IN PHASE I/ II STAGE OF DEVELOPMENT FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASE IN PATIENTS WITH LEUKEMIAS, LYMPHOMAS AND GENETIC BLOOD DISEASES.

  • Blood Disease
  • Chemotherapy
  • United States
  • World
  • Product Initiative
  • M-009 - DRUG PROFILE
  • FEATURED NEWS & PRESS RELEASES

In beta-thalassemia, a long-studied genetic disorder, a mutation impairs hemoglobin production, resulting in defective red blood cells (RBCs).

  • Blood Disease
  • Pathology
  • Therapy
  • United States
  • Product Initiative
  • GLOBAL THERAPEUTIC APHERESIS MARKET SIZE, BY PROCEDURE, 2014-2021, (USD MILLION)

In this process, the patient' s blood is passed through a system to remove defective blood components/ cells or to remove disease-provoking elements from the blood.

  • Blood Disease
  • World
  • Market Size
  • Cerus Corporation
  • Fresenius Group
  • Current Ongoing Trials for Rare Blood Diseases
  • 4.1.4 Development of Drugs for Rare Blood Diseases
  • Blood Disease
  • United States
  • World
  • Demand
  • Celgene Corporation

Genetic blood diseases (n=##) include SCID (Severe Combined Immune Deficiency) (n=##), thalassemia major (n=##), Wiskott-Aldrich syndrome (n=##), sickle cell disease (n=##), and several others.

  • Blood Disease
  • Leukemia
  • United States
  • Company
  • Bellicum Pharmaceuticals, Inc.
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • M-009 - DRUG PROFILE
  • Blood Disease
  • Pathology
  • Therapy
  • United States
  • Product Initiative
  • SMALL MOLECULES TO INHIBIT PRMT5 FOR HAEMOGLOBINOPATHIES AND SOLID TUMOURS - DRUG PROFILE
  • M-009 - DRUG PROFILE

In addition, treatment with ACE-## corrected anemia in animal models of chronic kidney disease and acute blood loss.

  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • RECENT DEVELOPMENTS IN BLOOD DISORDERS BIOSIMILARS
  • GLOBAL - BLOOD DISORDERS BIOSIMILARS MARKET (MILLION US$), 2014 - 2015

Blood disorders can affect any of the three main components of blood: Red blood cells, which carry oxygen to the body' s tissues, White blood cells, which fight infections, Platelets, which help blood to clot.

  • Blood Disease
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited
  • AGGRAM - HIT TEST - PRODUCT DESCRIPTION
  • DIAGNOSTIC TEST - ARTERIAL THROMBOSIS - PRODUCT DESCRIPTION
  • Blood Disease
  • Clinical Trial
  • Diagnostics
  • Healthcare
  • GlobalData's company
  • Fanconi Anemia - Drug Profiles
  • Blood Disease
  • United States
  • World
  • Product Initiative
  • Abeona Therapeutics, Inc.
  • SPINIT DEVICE - THROMBOCYTOPENIA ASSAY - PRODUCT DESCRIPTION

Biohit s sensitive and specific Celiac Disease Quick Test helps detect celiac disease patients among those with dyspeptic symptoms.

  • Blood Disease
  • Clinical Trial
  • Medical Device
  • Point Of Care Testing
  • GlobalData's company
  • Global blood disorders biosimilars market

However, the inclusion of end-stage kidney disease (ESRD) in the list of major diseases by the Zaraxio is the first approved biosmilar in the US in 2015 for the treatment of blood-related diseases.

  • Blood Disease
  • Biocon Limited
  • Hospira, Inc.
  • Sandoz Inc.
  • Teva Pharmaceuticals Ltd.
  • ABO-301 - Drug Profile
  • Fanconi Anemia - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016
  • Blood Disease
  • United States
  • World
  • Product Initiative
  • Bellicum Pharmaceuticals, Inc.

Cord blood stem cells are mainly used for the treatment of diseases related to blood - diseases such as leukaemia, anemia, etc.

  • Blood Disease
  • Stem Cell
  • World
  • Market Size
  • Cordlife Group Limited
  • Clinical Trial profile. 229 Trial Title
  • 5. All the trials included are unique trials.
  • Blood Disease
  • Clinical Trial
  • World
  • Product Initiative
  • Novartis AG
  • Clinical Trial profile. 21 Trial Title
  • Clinical Trial Profile Snapshots
  • Blood Disease
  • Hospital
  • World
  • Product Initiative
  • Alexion Pharmaceuticals, Inc.
  • THE PIPELINE SNAPSHOT

THE COMPANY CURRENTLY HAS FIVE ACTIVE REGISTRATIONS TWO IN CARDIOVASCULAR/ BLOOD DISEASES, TWO IN NEUROTHERAPEUTICS AND ONE IN INFECTIOUS DISEASE.

  • Blood Disease
  • United States
  • Company
  • Demand
  • Merck & Co., Inc.
  • Clinical Trial profile. 61 Trial Title
  • Clinical Trial Profile Snapshots
  • Blood Disease
  • Cell Therapy
  • Leukemia
  • World
  • Product Initiative

Global Blood Therapeutics, Inc. announced new results from its ongoing Phase I/ II GBT##-## study in sickle cell disease (SCD).

  • Blood Disease
  • United States
  • World
  • Product Initiative
  • Athersys, Inc.